Continuous infusion of PTH in vivo results in active bone resorption. To investigate the
molecular basis of the catabolic effect of PTH in vivo, we evaluated the role of OPG and RANKL, …

GSK‐3, a component of the canonical Wnt signaling pathway, is implicated in regulation of
bone mass. The effect of a small molecule GSK‐3 inhibitor was evaluated in pre‐osteoblasts …

Bone formation and resorption are tightly coupled under normal conditions, and the interaction
of osteoclast precursors with cells of the osteoblast lineage is a prerequisite for osteoclast …

Transforming growth factor-β (TGF-β) regulates osteoclastogenesis and osteoclast survival,
in part through the induction of osteoprotegerin (OPG), a protein known to inhibit osteoclast …

Teriparatide, human PTH (1‐34), a new therapy for osteoporosis, elicits markedly different
skeletal responses depending on the treatment regimen. In order to understand potential …

Parathyroid hormone (PTH) and glycogen synthase kinase‐3 (GSK‐3) inhibitor 603281‐31‐8,
administered once daily increased bone formation in vivo. We investigated the molecular …

The non‐mineral component of bone matrix consists of 90% collagenous, 10% non‐collagenous
proteins. These proteins regulate mineralization, growth, cell signaling and …

Regulator of G‐protein signaling‐2 (RGS‐2) belongs to a novel family of GTPase‐activating
proteins that rapidly turn‐off G‐protein coupled receptor signaling. RGS proteins contain a …

We have developed a high-content screening (HCS) assay to find activators of Wnt/Frizzled (Wnt/Fzd),
a pathway known to be important in bone formation. Utilizing primary human …

Osteoprotegerin (OPG), a secreted member of the tumor necrosis receptor superfamily, is a
potent inhibitor of osteoclast formation and bone resorption. Parathyroid hormone (PTH), a …